文献速递造血干细胞移植与细胞治疗白血病

聚乙二醇干扰素-2α在异基因造血干细胞移植后复发患者中诱导移植物抗白血病效应

Pegylated interferon-2α invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation.
PubMed 文献 · Blood Adv · 2019-01-01

这项前瞻性I/II期剂量递增临床试验在29例异基因造血干细胞移植后复发患者中,于再诱导化疗后给予聚乙二醇干扰素-2α(伴或不伴供者淋巴细胞输注),2年总生存率为31%(95%CI 17.3%-49.2%),拒绝历史队列7%的无效假设。治疗相关移植物抗宿主病和血液学毒性可通过计划性剂量调整管理。

要点

  • 移植后复发患者再诱导化疗后使用peg-IFNα,2年OS为31%(95%CI 17.3%-49.2%)。
  • peg-IFNα相关GVHD和血液学毒性可通过计划性剂量调整管理。
  • 治疗前调节性免疫细胞比例较高与更好的PFS和OS相关,且独立于GVHD。

核心结论

  • 异基因移植后复发患者再诱导化疗后给予peg-IFNα是诱导移植物抗白血病效应的合理策略,值得在更大规模多中心队列中研究。

研究设计与样本

  • 前瞻性I/II期剂量递增临床试验,纳入29例异基因造血干细胞移植后复发患者,试验注册号ACTRN12612000728831。

主要发现

  • 再诱导化疗后给予peg-IFNα(伴或不伴后续供者淋巴细胞输注)的2年总生存率为31%(95%CI 17.3%-49.2%),拒绝历史队列7%的无效假设。
  • peg-IFNα与移植物抗宿主病和血液学毒性相关,可通过计划性剂量调整管理。
  • 发生GVHD的患者无进展生存期最长,但其中多数患者最终仍进展。
  • 治疗前具有调节功能的免疫细胞群体(包括黏膜恒定T细胞、调节性T细胞和浆细胞样树突状细胞)比例较高与更好的PFS和OS相关,且独立于GVHD。

临床怎么用

  • 对于异基因造血干细胞移植后复发患者,可考虑在再诱导化疗后使用peg-IFNα以增强移植物抗白血病效应,同时监测和管理GVHD及血液学毒性。

局限性

  • 研究为单中心前瞻性I/II期试验,样本量29例,结果需在更大规模多中心队列中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic stem cell transplantation (SCT) is a curative therapy for patients with hematological malignancies related largely to an immunological graft-versus-leukemia (GVL) effect mediated by donor T cells and natural killer cells. Relapse of disease after SCT represents failure of GVL and is now the major cause of treatment failure. We sought to augment GVL effects in patients (n = 29) relapsing after SCT in a prospective phase I/II clinical trial of dose-escalated pegylated interferon-2α (peg-IFNα). The administration of peg-IFNα after reinduction chemotherapy, with or without subsequent donor lymphocyte infusion (DLI), resulted in a 2-year overall survival (OS) of 31% (95% confidence interval, 17.3%-49.2%), which rejects the null hypothesis of 7% generated by observations in an institutional historical cohort. As expected, peg-IFNα was associated with graft-versus-host disease (GVHD) and hematological toxicity, which was manageable with scheduled dose modifications. Progression-free survival (PFS) was greatest in patients who experienced GVHD, although the majority of those patients still eventually progressed. Higher PFS and OS were associated with pretreatment proportions of immune cell populations with regulatory function, including mucosal invariant T cells, regulatory T cells, and plasmacytoid dendritic cells, independent of any association with GVHD. Peg-IFNα administration after relapse thus constitutes a logical strategy to invoke GVL effects and should be studied in a larger, multicenter cohort. This trial was registered at www.anzctr.org.au as #ACTRN12612000728831.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Henden AS, Varelias A, Leach J, et al. Pegylated interferon-2α invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation. Blood Adv. 2019. PMID: 31648324. doi:10.1182/bloodadvances.2019000453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。